Moderna, Inc. (MRNA)
| Previous close | 76.61 |
| Open | 76.15 |
| Bid | 77.21 x 500 |
| Ask | 77.58 x 100 |
| Day's range | 75.95 - 78.08 |
| 52-week range | 62.55 - 170.47 |
| Volume | |
| Avg. volume | 3,793,409 |
| Market cap | 29.708B |
| Beta (5Y monthly) | 1.67 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -15.35 |
| Earnings date | 31 Oct 2024 - 04 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 123.05 |
PR NewswireCarisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the expansion of its in vivo chimeric antigen receptor macrophage and monocyte (together, "CAR-M") collaboration with Moderna, Inc. (Nasdaq: MRNA) to include the nomination of two targets for the treatment of autoimmune diseases. Carisma retains all rights in autoimmune disease beyond the two nominated
ZacksMRNA Gets Positive CHMP Opinion for Updated COVID-19 Jab
The Committee for Medicinal Products for Human Use recommends marketing authorization for Moderna's updated mRNA COVID-19 jab, Spikevax.
Investor's Business DailyModerna Stock's Three-Year Decline — Is It Time To Sell, Hold Or Buy?
Despite becoming one a household name during the pandemic, Moderna stock has mostly fallen over the past three years amid slow sales.
